Physicians' Academy for Cardiovascular Education

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017

Diverse study data confirm the rationale of intensive lipid-lowering

Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS

Imaging components of plaque not more informative than burden of plaque

Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium

Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective

Aug. 28, 2017

LDL-c still reduced after 1 year with siRNA against PCSK9

Aug. 28, 2017

PCSK9 inhibition works, but you can’t force biology

Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Changing therapeutic behaviour after FOURIER

Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 inhibitors: From bench to bedside

Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA

The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials

Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA

Lowering LDL-c for a longer period of time really matters

Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA

No J-shaped curve for efficacy in PCSK9 outcome trials

Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 outcome trials: The results put into perspective of other clinical developments

Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA

LDL lowering for CVD prevention: From hypothesis to axiom

Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?

Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA

Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time

Mar. 17, 2017

CV outcomes with a PCSK9 inhibitor: FOURIER study

Mar. 16, 2017

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
##SCROLLER_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##SCROLLER_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)

Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Can LDL go too low? Lessons from 25 years of cholesterol lowering

Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

Dr. Robert Giugliano summarizes what we have learned over the past decades about the effectiveness and safety of reducing LDL-c to very low values.

LDL-receptor expression correlates with the reduction in LDL-c in patients with homozygous FH on PCSK9 inhibitor treatment

Jan. 8, 2018 - Thedrez A, et al. - Arterioscler Thromb Vasc Biol. 2017

Ex vivo LDL-receptor expression is inversely associated with the plasma levels of LDL-c and apoB in HoFH patients before and after treatment with evolocumab.

FDA Approval for evolocumab as secondary prevention in CVD patients

Dec. 4, 2017 - news

Following FDA Priority Review, evolocumab is the only PCSK9 inhibitor approved to reduce risk of myocardial infarction, stroke and coronary revascularization in adults with established CVD.

Summary | PCSK9 inhibition across a wide spectrum of patients: One size fits all?

August 26, 2017 - Prof. Kees Hovingh (Amsterdam, the Netherlands)
August 26, 2017 - Prof. Kees Hovingh (Amsterdam, the Netherlands)

The need for additional therapies to lower LDL-c levels was discussed and subsequently the effect of PCSK9 inhibitors in different studies was explained in several patient populations.

Summary | Understanding new PCSK9 outcome data: From the LDL-c hypothesis to LDL-c causality

August 26, 2017 - Prof. John Chapman (Paris, France)
August 26, 2017 - Prof.  John Chapman (Paris, France)

Prof. Chapman briefly introduced the outcome trials on the two PCSK9 inhibitors evolocumab and alirocumab and explained in more detail the pathophysiology of atherosclerotic CVD.

PCSK9 LOF variants and low LDL-c levels not associated with neurocognitive impairment

Nov. 24, 2017 - Mefford MT et al. - Circulation 2017

Data of large prospective cohort of African-Americans suggest that life-long exposure to low PCSK9 levels and the resulting low levels of LDL-C do not have major effects on neurocognitive outcomes.

PCSK9 inhibitor lowers CV risk in peripheral artery disease and in high-risk patients with previous MI

Presented at AHA 2017 Scientific Sessions in Anaheim, CA, USA by Marc Bonaca and Marc Sabatine (Brigham and Women’s Hospital, Boston, MA, USA)

Nov. 21, 2017 - news

AHA 2017 New FOURIER analyses show benefit of treatment with evolocumab both in patiënts with PAD, and clinical factors in high-risk post-MI patients can predict extra high risk.

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

AHA 2017 - Anaheim, CA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

AHA 2017 PAD patients enrolled in the FOURIER trial who were treated with PCKS9 inhibitor evolocumab showed a higher absolute and relative CV event reduction, and a large reduction in limb events.

Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

AHA 2017 - Anaheim, CA, USA

Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

AHA 2017 Subanalysis of FOURIER shows that within the subgroup of patients with prior MI, a subgroup at extra high risk has greater benefit of LDL-c lowering with PCSK9 inhibitor evolocumab.

PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials

Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017
Lecture by Peter Sever, MD held at symposium on PCSK9 inhibition & Cardiovascular Outcomes:  Review of lipid targets and treatment strategies

This lecture was part of a CME accredited symposium: PCSK9 inhibition & Cardiovascular Outcomes: Review of lipid targets and treatment strategies held at ESC 2017 in Barcelona on August 26, 2017.